Oncology news and insights from leading researchers and cancer centers.
Greater New York Area
- Tweets 46,599
- Following 3,547
- Followers 21,061
- Likes 5,352
At #IMS2026, Pieter Sonneveld, MD, PhD (@ErasmusMC) sat down with us to discuss CAR T-cell therapy and bispecific antibodies moving to frontline #myeloma care and an EMN trial of CAR T vs transplant.
🎥 WATCH: hubs.li/Q04ym6Xk0
2
244
At #IMS2026, C. Ola Landgren, MD, PhD (@SylvesterCancer) explains how MRD negativity and newer therapies may move multiple #myeloma care past the question of transplant eligibility.
🎥 WATCH: hubs.ly/Q04ylVz10
2
1
391
🔎 From phase 3 CERVINO results for etentamig to MRD-guided ASCT deferral and new anito-cel data, Day 3 of #IMS2026 featured several key updates in multiple #myeloma.
Explore the full recap: hubs.ly/Q04yk0HL0
1
4
459
Peter Voorhees, MD (@AtriumHealth) discusses the CERVINO trial of the bispecific antibody etentamig that he is presenting at #IMS2026.
🎥 WATCH: hubs.li/Q04yky8L0
#Myeloma #Hematology #Oncology
2
351
Geoffrey Y. Ku, MD (@MSKCancerCenter) discusses the state of biomarkers in gastric/gastroesophageal junction cancers and where precision medicine still falls short.
🎥 WATCH: hubs.li/Q04yjYzv0
#GastricCancer #GEJCancer #GICancers #Oncology #PrecisionMedicine
1
1
4
400
📊 The 2026 Annual Report to the Nation on the Status of Cancer shows US cancer deaths keep falling as #LungCancer declines due to smoking cessation and screening, but rural and low-education gaps persist.
Read: hubs.ly/Q04yjVW60
#Oncology #CancerPrevention #PublicHealth
3
333
Hans Lee, MD (@SarahCannonDocs) joined us at #IMS2026 to explain new IMS/IMWG cure criteria for #myeloma and the meaning of durable CAR-T responses in these patients.
🎥 Watch the conversation: hubs.ly/Q04yk4Dk0
3
2
367
Targeted Oncology retweeted
Real-time #IMS26 insights? ✅ @SarahCannonDocs @DanaFarber @TheBianchiLab @MileHighMyeloma #mmsm @Myeloma_Society
2
4
1,156
🚨 Is autologous transplant losing its place in myeloma treatment?
@GKaurMD breaks down why CAR T and bispecifics are reshaping frontline care and where transplant still holds its ground. 🎥👇 targetedonc.com/view/kaur-de… #IMS2026 #MultipleMyeloma #MedTwitter
4
5
479
📢 FDA Approval Alert: The #FDA has approved belzutifan plus lenvatinib for advanced clear cell #RCC after PD-1/PD-L1 therapy, based on PFS and response rate benefit vs cabozantinib.
Read more: targetedonc.com/view/fda-app…
#KidneyCancer #ccRCC #Oncology #CancerTreatment
3
3
507
🔎 FDA News: An #FDA advisory panel has backed the Galleri MCED test for adults 50+, citing strong specificity, mixed sensitivity, and follow-up impacts as FDA weighs approval.
Read more about the decision: targetedonc.com/view/fda-pan…
#MCEDTest #CancerScreening #CancerDiagnosis
1
504
MRD-guided maintenance took center stage on Day 2 of #IMS2026, alongside new data on bispecific and trispecific therapies in multiple #myeloma.
🔎 Get the full recap of the day: targetedonc.com/view/ims-day…
#Hematology #Oncology #CancerTreatment
3
7
684
🔎 FDA News: LRRC15-targeting ADC SOT106 has gained #FDA fast track and orphan status for sarcomas, showing preclinical promise as it heads into a first-in-human trial.
Read more: targetedonc.com/view/sot106-…
#Sarcoma #Osteosarcoma #SoftTissueSarcoma #Oncology #CancerTreatment
3
5
599
Radiation oncology is evolving—and #ASTRO2026 could offer a look at where the field is headed. 🔎
In our latest podcast episode, @Raj_Singh_MD (@BaptistHealthSF) breaks down key data on de-escalation, brain mets, and more.
🎧 Listen now: targetedonc.com/view/astro-2…
2
5
666
🩺 A new IMS/IMWG consensus definition requires 5 years of treatment-free, MRD-negative remission before multiple #myeloma can be called cured.
Read more: targetedonc.com/view/global-…
#IMS2026 #Hematology #Oncology #CancerTreatment
7
553
📢 FDA News: The #FDA has approved lirafugratinib (Lyrfigtu) for adults with previously treated unresectable, locally advanced or metastatic #cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.
Read more: targetedonc.com/view/fda-app…
#Oncology #CancerTreatment
1
8
568
Shubham Pant, MD (@UTMDAnderson) discusses the expanding pipeline of RAS-directed agents beyond #daraxonrasib for patients with #PancreaticCancer.
🎥 WATCH: targetedonc.com/view/pant-pa…
#Oncology #CancerTreatment #GICancers #PDAC
2
321
Hans Lee, MD (@SarahCannonDocs) discusses the importance of BCMA-targeted therapy and the differences between CAR T and bispecific antibody therapy in multiple #myeloma.
🎥 WATCH: targetedonc.com/view/priorit…
#CARTCellTherapy #Bispecifics #Hematology #Oncology #CancerTreatment
1
1
9
618
A new analysis tracks life-years saved from #BloodCancer therapies, revealing breakthrough inflection points, gaps, and inequities in access.
💬 Dr Andy Kolb (@BloodCancerUtd) breaks down the key findings: targetedonc.com/view/life-ye…
#Leukemia #Lymphoma #Hematology #Oncology
2
3
512